Display Settings:

Format

Send to:

Choose Destination
See comment in PubMed Commons below
J Infect Dis. 2012 Oct 1;206(7):1030-40. Epub 2012 Jul 30.

Substitution of rifapentine for rifampin during intensive phase treatment of pulmonary tuberculosis: study 29 of the tuberculosis trials consortium.

Collaborators (195)

Johnson JL, Mugerwa RD, Mayanja-Kizza H, Muzanye G, Gitta P, Okwera A, Lamunu D, Nsubuga P, Joloba M, Morgan K, Ogwang S, Mulumba Y, Nakibali JG, Kimera J, Ssaku E, Weiner MH, Wing R, Wing D, Uribe J, Engle M, Calderin A, Fernandez M, Weis S, King B, Turk L, Stevenson G, Helal J, Shafer N, Dunbar D, Jost K, Cayla JA, Miró JM, Moreno A, Millet JP, del Baño L, Martinez JA, Sambeat M, Sanchez F, López Colomés JL, de Souza M, Jiménez M, Milà C, Lacasa XM, Falcó V, Santín M, Alcaide F, Gonzalez J, Martin N, El-Sadr W, Padayatchi N, Bamber S, Chinappa ST, Hirsch-Moverman Y, Naidoo V, Mnguni N, Mthethwa T, Gumede Z, Ganas K, Hesseling A, Cotton M, Diacon A, Groenewald N, Lawn C, Simmonds V, Noveljic Z, Venter A, Guy E, Hamill R, Nickson R, Goodrich K, Conde MB, Efron A, Loredo C, Mello F, Marsico AG, de Oliveira Vieira GB, Martinson N, Xuza Y, Hunt J, Efron A, Trussler J, Schluger NW, Burzynski J, Lozano V, Wolk M, Ebrahimzadeh A, Murphy AL, Weiner MH, Engle M, Pavon H, Jimenez J, Sadkowski LC, Nahid P, Hopewell P, Merrifield C, Rudoy I, Israel J, Babst A, Mangura BT, Reichman LB, Lardizabal AA, Patarawalla A, Leus MC, Anokute V, Burday M, Sickles D, Sterling TR, Kerrigan A, Smith T, Wright A, Reves R, Burman W, Tapy J, Belknap R, Sanchez G, Hildred G, Luna L, Narita M, Pecha M, Ragland M, Le L, Pass J, Nahid P, Nhung NV, Hanh N, Merrifield C, Catanzaro A, Moser KS, Tracy MJ, Francisco VP, Davis J, Reed S, Peter CR, Hamilton CD, Stout J, Holland D, Mosher A, Hecker E, Bargothi S, Gordin FM, Benator D, Conwell DS, Menzies D, Schwartzman K, Greenaway C, Pelletier M, Valiquette C, Plaisir P, Thibert L, Dorman S, Chaisson RE, Maltas G, Fisher J, Hooper N, Jones BE, Rayos E, Molina P, Luken C, Sum S, Gotuzzo EJ, Zamudio C, Seas C, Hurtado C, Levano L, Pantoja C, Sharma A, Wang S, Batra K, Davis H, Burks S, Feng PJ, Borisov A, Sharma A, Bozeman L, Bliven-Sizemore E, Hall L, Allen C, Doherty C, Haile B, Carter C, Fagley M, Gross L, Henderson C, Jackson M, Bozeman L, Kaminski D, Toney S, Metchock B, Diem L, Sikes D, Hartline D, Temporado D, Neaton J, Kaplan J, Ashkin D.

Author information

  • 1Johns Hopkins University School of Medicine, Baltimore, Maryland 21231, USA. dsusan1@jhmi.edu

Abstract

BACKGROUND:

Rifapentine administered 5 days per week has potent activity in mouse models of antituberculosis chemotherapy, but efficacy and safety data are limited in humans. We compared the antimicrobial activity and safety of rifapentine vs rifampin during the first 8 weeks of pulmonary tuberculosis treatment.

METHODS:

In total, 531 adults with sputum smear-positive pulmonary tuberculosis were randomized to rifapentine 10 mg/kg/dose or rifampin 10 mg/kg/dose, administered 5 days per week for 8 weeks (intensive phase), with isoniazid, pyrazinamide, and ethambutol. Coprimary outcomes were negative sputum culture on liquid and on solid media at completion of intensive phase.

RESULTS:

Negative cultures on solid media occurred in 145 of 174 participants (83.3%) in the rifampin group and 171 of 198 participants (86.4%) in the rifapentine group (difference, 3.0%; 95% confidence interval [CI]: -4.3, 10.5); negative cultures in liquid media occurred in 110 of 169 (65.1%) in the rifampin group and 133 of 196 (67.9%) in the rifapentine group (difference, 2.8%; 95% CI: -6.9, 12.4). Among 529 participants who received study therapy, 40 of 254 participants (15.7%) in the rifampin group and 40 of 275 participants (14.5%) in the rifapentine group prematurely discontinued treatment (P=.79).

CONCLUSIONS:

The rifapentine regimen was safe but not significantly more active than a standard rifampin regimen, by the surrogate endpoint of culture status at completion of intensive phase. Assessment of higher exposures to rifapentine for tuberculosis treatment is warranted. Clinical Trials registration: NCT00694629.

PMID:
22850121
[PubMed - indexed for MEDLINE]
Free full text
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for HighWire
    Loading ...
    Write to the Help Desk